PA5-66385

antibody from Invitrogen Antibodies

Targeting: AKIP1 BCA3, C11orf17

Immunocytochemistry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-66385

Provider

Invitrogen Antibodies

Product name

AKIP1 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant full-length protein

Description

Immunogen sequence: VDRRSLQRSAR LALEVLERAK RRAVDWHALE RPKGCMGVLA REAPHLEKQP AAGPQRVLPG E

Concentration

0.05 mg/mL

References

Submitted references

Ebola virus VP35 hijacks the PKA-CREB1 pathway for replication and pathogenesis by AKIP1 association.

Zhu L, Gao T, Huang Y, Jin J, Wang D, Zhang L, Jin Y, Li P, Hu Y, Wu Y, Liu H, Dong Q, Wang G, Zheng T, Song C, Bai Y, Zhang X, Liu Y, Yang W, Xu K, Zou G, Zhao L, Cao R, Zhong W, Xia X, Xiao G, Liu X, Cao C
Nature communications 2022 Apr 26;13(1):2256

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunofluorescent staining of AKIP1 in human cell line SiHa shows localization to nucleoplasm. Samples were probed using an AKIP1 Polyclonal Antibody (Product # PA5-66385).

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

The EBOV VP35 associates with AKIP1. a Lysates of HepG2 cells expressing Flag-VP35 or Flag were subjected to anti-Flag immunoprecipitation and analyzed by immunoblotting. b - d , f Lysates of HEK293 cells transfected with the indicated plasmids were subjected to anti-Flag immunoprecipitation and analyzed by immunoblotting. e Lysates of HEK293 cells transfected with the indicated plasmids were treated with/without RNase (the mixture of RNase A and RNase T1) and analyzed using immunoprecipitation and immunoblotting. g HepG2 cells were cotransfected with GFP-VP35 (or GFP vector) and Myc-AKIP1 and immunostained with an anti-AKIP1 antibody (red). At least three independent repeats were performed in all of the experiments.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 2 EBOV VP35 interacts with AKIP1 in the viral inclusion bodies of HepG2 cells infected with EBOV or trVLPs. a HepG2 cells infected with Zaire EBOV (strain Mayinga) (MOI = 10) for 72 h were analyzed by immunostaining with anti-VP35 (green) and anti-AKIP1 (red) antibodies (upper panel) or anti-VP35 antibody only (lower panel). b HepG2 cells infected with live EBOV (MOI = 10) for 72 h or transfected with the EBOV minigenome (p0) for 48 h were subjected to an in situ PLA assay with anti-VP35 and anti-AKIP1 antibodies (red), and immunostaining with an anti-NP antibody (green). Arrows: VP35-AKIP1 complexes in the viral inclusion bodies of EBOV (upper panel) or trVLPs (lower panel). At least three independent repeats were performed in all of the experiments.